What question did this study set out to answer?

The aim is to evaluate the efficacy of bispecific antibodies in selectively activating 4-1BB in tumor environments to enhance immune responses.

Tumor-Selective Activation of 4-1BB Receptor via Bispecific Antibody Combinations

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the efficacy of bispecific antibodies in selectively activating 4-1BB in tumor environments to enhance immune responses.
Generated Fc-silent bispecific antibodies targeting 4-1BB and HER2.
Co-cultured 4-1BB reporter cells with HER2-expressing tumor cells to assess signaling.
Conducted in vitro assays using primary human T cells for cytokine production and tumoricidal activity.
Evaluated in vivo efficacy using PBMC-engrafted NOG mice with HER2-positive tumor cells.
Bispecific antibodies enhance 4-1BB signaling when targeting the same epitope on 4-1BB and different epitopes on HER2.
Strong IL-2 release occurs in the presence of HER2-positive tumor cells.
The combination of bispecific antibodies and T cell engagers improved antitumor activity and T cell infiltration compared to single agents.

No takes yet. Share an insight, caveat, or question.

This report demonstrates enhanced 4-1BB activation in tumors using bispecific antibodies, suggesting new cancer therapies.

Diby et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark